These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Angiotensin receptor antagonists. A new class of antihypertensive agents]. Mann J Dtsch Med Wochenschr; 1996 Apr; 121(17):568-71. PubMed ID: 8620827 [No Abstract] [Full Text] [Related]
44. New angiotensin-II blocker. Lilley LL; Guanci R Am J Nurs; 1996 Mar; 96(3):20. PubMed ID: 8607540 [No Abstract] [Full Text] [Related]
45. Irbesartan slows the development of diabetic nephropathy by up to 70% in hypertensive diabetic patients. Cardiovasc J S Afr; 2001; 12(4):242-3. PubMed ID: 11766619 [No Abstract] [Full Text] [Related]
46. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Franscini LM; Von Vigier RO; Pfister R; Casaulta-Aebischer C; Fossali E; Bianchetti MG Am J Hypertens; 2002 Dec; 15(12):1057-63. PubMed ID: 12460701 [TBL] [Abstract][Full Text] [Related]
47. Pharmacotherapy for prehypertension--mission accomplished? Schunkert H N Engl J Med; 2006 Apr; 354(16):1742-4. PubMed ID: 16537661 [No Abstract] [Full Text] [Related]
48. [Focus on compliance. Rapid goal attainment in hypertension]. Riem L MMW Fortschr Med; 2011 Jan; 153(4):51. PubMed ID: 22165621 [No Abstract] [Full Text] [Related]
49. Comment on "Effects of long-term angiotensin II AT-1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats". Willenheimer R Cardiovasc Res; 1999 Aug; 43(2):500-1. PubMed ID: 10536680 [No Abstract] [Full Text] [Related]
50. Efficacy of angiotensin II antagonists in hypertension. Spence JD Can J Cardiol; 1999 Nov; 15 Suppl F():33F-5F. PubMed ID: 10579750 [TBL] [Abstract][Full Text] [Related]
51. [Health economic aspects of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. Schute LL Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1448; author reply 1448. PubMed ID: 15213879 [No Abstract] [Full Text] [Related]
52. The angiotensin II receptor antagonist losartan: a new advance in the treatment of hypertension. Lacourcière Y Can J Cardiol; 1995 Aug; 11 Suppl F():45F-48F. PubMed ID: 7664218 [TBL] [Abstract][Full Text] [Related]
53. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. Liberopoulos E; Christides D; Elisaf M J Hypertens; 2002 Feb; 20(2):347. PubMed ID: 11821722 [No Abstract] [Full Text] [Related]
55. The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective. Kurland L Minerva Med; 2003 Aug; 94(4):251-8. PubMed ID: 14605589 [TBL] [Abstract][Full Text] [Related]
56. [Effect of angiotensin receptor blockers on hemodynamic aspects during myocardial infarction]. Turubarova NA; Leunov VV; Tashchuk VK Lik Sprava; 2002; (3-4):43-4. PubMed ID: 12145889 [TBL] [Abstract][Full Text] [Related]
57. [Evidence based treatment of diabetic nephropathy]. Sugimoto T Nihon Rinsho; 2002 Oct; 60 Suppl 10():294-300. PubMed ID: 12430244 [No Abstract] [Full Text] [Related]
59. [Treatment of hypertension can do more. Using chances for organ protection]. MMW Fortschr Med; 2006 Nov; 148(45):58-9. PubMed ID: 17615753 [No Abstract] [Full Text] [Related]
60. [Arterial hypertension in adipose patients. Rationale for a prospective medical care study in the family physician practice]. Bramlage P; Sharma AM; Kirch W MMW Fortschr Med; 2004 Apr; 146(17):47. PubMed ID: 15224906 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]